Photo from wikipedia
Commentary on : Raskob GE, van Es N, Verhamme P, et al . Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med . 2018 Feb 15;378:615–624. Low-molecular-weight heparin… Click to show full abstract
Commentary on : Raskob GE, van Es N, Verhamme P, et al . Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med . 2018 Feb 15;378:615–624. Low-molecular-weight heparin (LMWH) is the standard of care for treatment of cancer-associated venous thromboembolism (VTE).1 2 This recommendation is supported largely by a landmark randomised controlled trial (RCT) that showed that patients with cancer who received 6 months of dalteparin instead of warfarin (after an initial 5–7 days of dalteparin) had a 52% risk reduction for recurrent VTE.3 However, LMWH injections can be painful as well as anxiety provoking. A pill would be a welcome alternative for most patients, but only if it is as …
Journal Title: BMJ Evidence-Based Medicine
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!